Diagnosing Minimal Hepatic Encephalopathy
Launched by ESBJERG HOSPITAL - UNIVERSITY HOSPITAL OF SOUTHERN DENMARK · Jun 22, 2022
Trial Information
Current as of July 23, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion criteria for patients with liver cirrhosis:
- • 1. Age\> 18
- • 2. Liver cirrhosis verified by biopsy or appropriate clinic and biochemistry as well as imaging.
- • 3. Written informed consent
- • 4. Speaks and understands Danish
- For the subgroup with liver cirrhosis and normal cognition:
- • 1. Normal result in PSE and CRT testing and clinical examination without evidence of HE
- For the subgroup with liver cirrhosis and minimal hepatic encephalopathy:
- • 2. Abnormal result in PSE and / or CRT test, but oriented in time, place and own data.
- For the subgroup with liver cirrhosis and HE grade 2, the following applies:
- • 3. Abnormal PSE and CRT result and / or disoriented in time, place or own data and / or asterixis or other clinical symptoms of HE
- • 4. Ability to collaborate on the performance of CRT test, PSE test and EEG
- Inclusion criteria healthy:
- • 1. Liver healthy
- • 2. Age over 18 years
- • 3. Formal education ≤ 14 years
- • 4. Written informed consent
- • 5. Speaks and understands Danish
- Inclusion criteria for pre-cirrhosis liver disease:
- As for healthy controls plus:
- • 1. In our local outpatient clinic
- • 2. Proven pre-cirrhosis liver disease
- Exclusion Criteria:
- • 1. Organic brain disease (eg previous epilepsy, apoplexy, dementia)
- • 2. Hyponatraemia (Na \<124 mmol / L)
- • 3. Sepsis one week prior to tests.
- • 4. Heart failure (EC less than 30% or NYHA class III and IV)
- • 5. Severe chronic obstructive pulmonary disease (GOLD stage 3 and 4 ie FEV1 / FVC below 0.7 and FEV1 \<50% of expected value)
- • 6. Highly controllable diabetes (HbA1C\> 60 mmol / mol)
- • 7. Renal failure (eGFR below 60)
- • 8. Known neurological diseases (epilepsy, stroke, dementia)
- • 9. Intake of coffee or alcohol 6 hours before tests and change of dose in psychoactive drugs within 6 days of the test (morphine, antipsychotics, antidepressants) -
About Esbjerg Hospital University Hospital Of Southern Denmark
Esbjerg Hospital, part of the University Hospital of Southern Denmark, is a leading clinical research institution dedicated to advancing healthcare through innovative research and comprehensive patient care. With a focus on multidisciplinary collaboration and state-of-the-art facilities, the hospital conducts a wide range of clinical trials aimed at improving treatment outcomes and enhancing patient quality of life. Its commitment to scientific excellence and ethical standards positions Esbjerg Hospital as a pivotal contributor to the advancement of medical knowledge and the development of new therapies in southern Denmark and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Esbjerg, , Denmark
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials